UPLC-Q-TOF-MS和UPLC-QqQ-MS对银丹心脑通口服给药后吸收成分的鉴定及主要化合物的药代动力学评价†,RSC Advances

当前位置： X-MOL 学术 › RSC Adv. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

UPLC-Q-TOF-MS和UPLC-QqQ-MS对银丹心脑通口服给药后吸收成分的鉴定及主要化合物的药代动力学评价†
RSC Advances ( IF 3.9 ) Pub Date : 2018-04-26 00:00:00 , DOI: 10.1039/c7ra12659j
Leilei Gong ₁ , Haiyu Xu ₁ , Huijun Yuan ₂ , Lan Wang ₁ , Xiaojie Yin ₁ , Moqi Fan ₃ , Long Cheng ₄ , Xiaojing Ma ₁ , Rixin Liang ₁ , Hongjun Yang ₁

Affiliation

银丹心脑通胶囊（YDXNT）是一种传统的中药配方，几十年来一直用于治疗心脑血管疾病。以前的研究主要集中在体外和体内评估 YDXNT 的药理特性和主要化合物。然而，体内的多种生物活性化合物仍然知之甚少。本研究采用 UPLC-Q-TOF-MS 联合 UPLC-QqQ-MS 的综合策略检测口服 YDXNT 后血浆中的吸收成分和主要化合物的药代动力学。UPLC-Q-TOF-MS 用于检测大鼠口服给药后血浆中吸收的成分及其代谢物。共鉴定或初步表征了 52 种成分，包括 44 种原型化合物和 8 种代谢物。然后，选择九种主要化合物（槲皮素、异鼠李素、山柰酚、银杏内酯 A、银杏内酯 B、银杏内酯 C、白果内酯、丹参酮 IIA 和丹酚酸 B）使用 UPLC-QqQ-MS 进一步研究 YDXNT 的药代动力学行为。九种主要成分的浓度在 27 范围内。^-1。该研究为快速定性分析吸收的成分和评估口服给药后 YDXNT 主要成分的药代动力学提供了一种系统方法。更重要的是，这项工作提供了有关生物活性化合物鉴定和阐明其作用机制以及 YDXNT 药理作用的关键信息。

"点击查看英文标题和摘要"

Identification of absorbed constituents and evaluation of the pharmacokinetics of main compounds after oral administration of yindanxinnaotong by UPLC-Q-TOF-MS and UPLC-QqQ-MS†

Yindanxinnaotong capsule (YDXNT), a traditional Chinese formula, has been used to treat cardio-cerebrovascular diseases for several decades. Previous research has focused on evaluating the pharmacological properties and main compounds of YDXNT in vitro and in vivo. However, the multiple bioactive compounds in vivo remain poorly understood. In the present research, an integrative strategy using UPLC-Q-TOF-MS combined with UPLC-QqQ-MS was employed to detect the absorbed constituents and investigate the pharmacokinetics of main compounds in the plasma after oral administration of YDXNT. UPLC-Q-TOF-MS was developed to detect the absorbed constituents and their metabolites in the plasma after oral administration in rats. A total of 52 constituents, including 44 prototype compounds and 8 metabolites, were identified or tentatively characterized. Then, nine main compounds (quercetin, isorhamnetin, kaempferol, ginkgolide A, ginkgolide B, ginkgolide C, bilobalide, tanshinone IIA, and salvianolic acid B) were chosen to further investigate the pharmacokinetic behavior of YDXNT using UPLC-QqQ-MS. The concentration of nine main constituents were in the range of 27.85–76.54 ng mL⁻¹. This research provides a systematic approach for rapid qualitative analysis of absorbed constituents and for evaluating the pharmacokinetics of the main ingredients of YDXNT following its oral administration. More importantly, this work provides key information on the identification of bioactive compounds and the clarification of their action mechanisms, as well as on the pharmacological actions of YDXNT.

更新日期：2018-04-26

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>